相关实验视频

Updated: Feb 26, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

患有TP53突变骨髓增殖性新生瘤的患者的风险分层

Benjamin Rolles^1,2,3,4, Cilomar Martins de Oliveira Filho^5,6, Nathan Fergusson⁷

¹Division of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.

|February 24, 2026

概括

具有TP53突变的骨髓增殖性瘤 (MPN) 患者可以使用新模型更好地分层风险. 该模型识别了具有TP53突变的高风险患者,以改善整体生存 (OS) 结果.

科学领域:

血液学血液学血液学
在瘤学瘤学.
遗传学遗传学是一个

背景情况:

骨髓增殖性新生瘤 (MPN) 中的TP53突变与白血病转变风险的增加有关.
然而,并非所有具有TP53突变的MPN患者都会进展,因此需要更好的风险分层.
准确的预后对于管理MPN和TP53突变患者至关重要.

研究的目的:

开发一种精细的风险分层模型,用于TP53突变的MPN患者.
在这个患者队列中确定影响整体生存 (OS) 的关键因素.
为了改善TP53突变MPN管理的临床决策.

主要方法:

分析了来自四个专门的癌症中心的1540名MPN患者的数据.
多变量分析以确定TP53突变MPN中OS的预后因素.
基于已识别的变量开发和验证基于风险评分系统.

主要成果:

骨髓纤维化,多次TP53突变状态和更高的PHANTM得分与更糟糕的OS有关.
开发了一个风险模型,将患者分为高风险,中等风险和低风险组.
平均寿命差异很大:0.5年 (高风险),2.3年 (中等风险) 和6.3年 (低风险).

结论:

一个新的评分系统有效地完善了TP53突变MPN患者的风险分层.
该模型有助于识别需要更密切监测和量身定制治疗的高风险个体.
这些发现支持改善慢性期MPN与TP53异常的预后和管理策略.

更多相关视频

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...